Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 2B/3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors.
Recent Articles
- Vital Battery Metals Launches New Financing Round for Growth
- Lupaka Gold Corp: Updates on Arbitration Claim Progress
- Acceleware Ltd. Reports Strong Growth in Fourth Quarter Results
- Important Class Action Information for Ultra Clean Investors
- Fisher Investments Celebrates Prestigious Equity Management Award
- Blackpearl Group Strengthens US Presence with New COO
- Understanding Class Action for Investors of TFI International
- Investors Considering Class Action Against Sana Biotechnology, Inc.
- Understanding the Class Action Against enCore Energy Corp: What Investors Need to Know
- Exploring Ingalls Shipbuilding's Commitment to National Defense
- NBCA Hall of Fame Invites Nominations for Celebrated Awards
- Roch Dog Research Exposes Hotel Industry's Pet Fee Gaps
- Daiso Expands with New Store Featuring Unique Product Lines
- Projected Smart Transportation Growth: A Comprehensive Review
- Consolidated Lithium Secures Funds Through Successful Financing
- Marimaca Copper Corp. Launches Trading on ASX Amid Updates
- Broadwind Secures Major Deal for Innovative Power Solutions
- Iceland Seafood International hf Unveils 3.5-Year Bond Sale
- Carrum Health Expands Network: 90% of Americans Covered
- Community Healthcare Trust Sets First Quarter Earnings Call Date
- Innovative Solutions: Amygdala Neurosciences and ANS-858 in Addiction Treatment
- Experience the Joy of Brunch with Another Broken Egg Cafe
- WF International Limited Completes Successful IPO for Growth
- Caliber Public Safety Enhances RMS with New Crash Reporting Tool
- Understanding the GSK Securities Fraud Lawsuit: Key Insights
- Lockmasters Strengthens Portfolio with Signals Defense Acquisition
- Firefighters Advocate for Essential Public Service Funding
- SoundHound AI Faces Class Action Over Misleading Statements
- Oportun Secures $187.5 Million Warehouse Funding Deal
- Exciting Launch of IGT Wheel of Fortune Video Poker Game
- Autodesk Sees Leadership Change as Betsy Rafael Steps Down
- Discover Cutting-Edge Cybersecurity Innovations at OpenSSL Event
- Warner Bros. Discovery Highlights Upcoming Q1 2025 Earnings Call
- CenterPoint Energy, Inc. Announces Upcoming Q1 2025 Earnings Call
- Getty Images and Shutterstock Move Forward Amid Regulatory Scrutiny
- WSP Global Inc. Unveils Q1 2025 Results and Shareholder Meeting
- Quorum Information Technologies Reveals Upcoming Earnings Results
- FTG to Publish Q1 2025 Financial Results and Conference Details
- Shattuck Labs Set to Showcase Innovations at Healthcare Conference
- Brown & Brown, Inc. Prepares for 2025 Earnings Release Event
- reAlpha Tech Corp. Financial Performance Overview and Insights
- Nexus Industrial REIT Set to Release Exciting Q1 Results
- Silynxcom Ltd. Completes Successful Public Offering for Growth
- Navigating Uncertainty: Opportunities Ahead with American Century
- e.l.f. Beauty’s Investors: Join the Securities Class Action
- AES Corporation to Host First Quarter 2025 Financial Call
- Newmark Facilitates Major $105M Office Building Sale
- Jewelers Mutual Group Expands Global Reach with Acquisition
- OLIVEDA International's Exciting International Hydroxytyrosol Award
- US Capital Global Breaks Records with Impressive Financing Growth